Preclinical data updates for early-stage programs (EVX-V1) are low-impact catalysts at a $26M market cap. The stock may see minimal short-term movement from this scientific conference presentation. Monitor for next clinical-stage milestone (e.g., Phase 1 initiation or IND filing) or partnership news for meaningful re-rating.
Price Chart
Executive Summary
Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1, showing AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice. The data support the multi-component vaccine concept but is preclinical — no new clinical milestones, no regulatory action, and no financial figures were disclosed in the press release.
Key Facts
- Data presented at International Herpesvirus Workshop 2026 in Montreal
- New data show AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice
- EVX-V1 combines novel AI-discovered B-cell and T-cell antigens with AI-optimized versions of established CMV vaccine antigens
- No licensed CMV vaccine exists currently
- No financial data, clinical trial results, or regulatory milestones mentioned
Financial Impact
No financial figures disclosed; preclinical data only — no revenue or earnings impact
Risk Factors
- EVX-V1 is preclinical — years away from potential approval and commercialization
- No CMV vaccine has been approved despite decades of research, highlighting high scientific risk
- Company has no disclosed revenue stream and requires additional capital to advance pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3325846 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access